Eli Lilly’s experimental oral drug, orforglipron, has demonstrated impressive results in clinical trials for weight loss and diabetes management. Among diabetic participants, the drug achieved an average weight loss of 7.9% (approximately 7.2 kg), surpassing the 6% observed with Novo Nordisk’s injectable Ozempic. Orforglipron also reduced blood sugar levels by 1.3%, slightly less than Ozempic, but its oral administration marks a significant innovation in treatment options. The drug,...